Journal of cancer research and therapeutics最新文献

{"title":"Radium brachytherapy a predecessor to modern brachytherapy: A historical review from an Indian perspective.","authors":"Kuppusamy Thayalan, Ramamoorthy Ravichandran","doi":"10.4103/jcrt.jcrt_945_24","DOIUrl":"10.4103/jcrt.jcrt_945_24","url":null,"abstract":"<p><strong>Abstract: </strong>The discovery of X-rays and radium formed the basis of radiation therapy. Radium was the first radioisotope used in medicine in the form of surface mold, intracavitary, and interstitial implants, which is a highly conformal form of radiation therapy. India was one of the early users of radium, and Colonel Vaughan J.C. used 10 mg of radium at Ranchi. Major V Arthur Ponnaiah, was appointed as a radium safety officer, Barnard Institute of Radiology, Chennai, the first in India. The methods, Sievert integral, Manchester system, and Patterson-Parker rules, along with milligram-hour and millicurie-destroyed per square cm, were used in dosimetry. K Munjunath Rai (Chennai), P. K. Haldar (Agra), J. P. Sinha (Patna), and M.L. Aggarwal (Amritsar) were the pioneers of earlier radium applications in India. Y. Siddique had an exclusive radiation therapy training and was awarded by the Faculty of Radiologists (Present FRCR), London. Tata Memorial Hospital (TMH) established the first Radon plant in India under the physicist Ramaiah Naidu. Due to its long half-life, loss of sources, chances of leakage of radioactive material, and bent needles, radium was withdrawn from hospitals and replaced by a Manual Cs-137 kit, supplied by the Bhabha Atomic Research Centre (BARC). Later, Iridium-192 wires were used for manual interstitial implants, followed by remote after-loading systems. Establishment of the specialty of radiology and taking over radium from the purview of surgeons were a challenge in many hospitals. The journey of radium application was an early milestone of cancer therapy management, which was built over the sacrifices of many Indian surgeons, radiologists, and physicists. This paper reviewed the use of radium, from information collected from the individuals and hospitals who had the opportunity to work with them.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 5","pages":"982-988"},"PeriodicalIF":1.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145180683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Theranostics and personalized radiopharmaceuticals.","authors":"Sushant Sushant, Daya Nanad Sharma, Surendra Kumar Saini, Mrinalini Mrinalini, Prateek Maurya, Yamini Dharmashaktu","doi":"10.4103/jcrt.jcrt_1718_24","DOIUrl":"10.4103/jcrt.jcrt_1718_24","url":null,"abstract":"<p><strong>Abstract: </strong>Theranostics represents a novel approach in modern medicine, merging diagnostic and therapeutic methods into a unified framework tailored to individual patient needs. The current review explores the impact of personalized radiopharmaceuticals on the evolution of theranostics, particularly within oncology. The development of these specialized agents has revolutionized the way diseases are detected and treated, offering a more precise method that targets specific molecular features of tumors. By combining the ability to diagnose and treat with the same radiopharmaceutical, theranostics enables a more focused and efficient treatment pathway, minimizing adverse effects while enhancing therapeutic success. Personalized radiopharmaceuticals play a crucial role in this approach, offering the ability to monitor disease activity and therapeutic response in real time, thus providing critical insights for ongoing care. Integrating these advanced techniques into clinical practice is paving the way for more individualized cancer treatment, aligning with the broader goal of precision medicine. As this field advances, theranostics is expected to significantly improve patient outcomes and quality of life, marking a significant leap forward in personalized cancer care.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 5","pages":"989-994"},"PeriodicalIF":1.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145180721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatoid carcinoma of pancreas: Diagnostic challenges and literature review.","authors":"Ayush Dubey, Sujan K Voni, Snehasis Pradhan, Subhashree S Dash, Soumya Surath Panda","doi":"10.4103/jcrt.jcrt_854_25","DOIUrl":"10.4103/jcrt.jcrt_854_25","url":null,"abstract":"<p><strong>Abstract: </strong>Hepatoid carcinomas are a set of extrahepatic neoplasms representing focal hepatocellular carcinoma on morphology and immunohistochemistry. Hepatoid carcinoma is reported primarily in the ovary and stomach, but its presence in the urinary tract, lung, and biliary tract has also been reported. Clinical presentation, diagnosis, treatment, and prognosis of pancreatic hepatoid carcinomas are not well understood due to the rarity of available literature. Our case was a female of 33 years of age who had pain in her abdomen for three months. Serum carcinoembryonic antigen was raised, and alpha-fetoprotein was normal at baseline. A contrast-enhanced computed tomography scan of the abdomen, pelvis, and thorax revealed a pancreatic body mass with regional nodal metastases. Whole-body positron emission tomography/computed tomography scan showed the mass in the body of the pancreas encasing the splenic vein and splenic-portal confluence with regional nodal involvement. Biopsy and immunohistochemistry of the pancreatic mass revealed pancreatic hepatoid carcinoma. Post-discussion in multidisciplinary tumor board, it was found to be unresectable and hence started on modified FOLFIRINOX for four cycles, following which the patient developed multiple liver lesions, eastern cooperative oncology group performance status deteriorated to IV, following which the patient kept on best supportive care and died after four months. Due to the rarity of this tumor and as per the limited literature available, the mainstay treatment for pancreatic hepatoid carcinoma remains complete surgical resection with significantly improved survival. The prognosis cannot be predicted precisely due to a lack of evidence-based data.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 5","pages":"1075-1078"},"PeriodicalIF":1.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145180756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancers in adolescents and young adults (AYA) population: 5-year experience from a cancer registry in India.","authors":"Mahbooba Khazir, Mohammad Akram, Ruquiya Afrose, Mohd Shadab Alam, Mohsin Khan","doi":"10.4103/jcrt.jcrt_1739_24","DOIUrl":"10.4103/jcrt.jcrt_1739_24","url":null,"abstract":"<p><strong>Introduction: </strong>The distribution of cancer burden is unequal across the different age groups. The AYA age group have been defined by the National Cancer Institute as diagnoses occurring between the ages of 15 and 39. This age group shows the different features in terms of cancer biology, risk factors, prognosis etc., as compare to the other age groups.</p><p><strong>Material and methods: </strong>This was a retrospective observational study. Data collection was done from 2017 to 2021. Data was collected from Hospital Based Cancer Registry (HBCR) that registers all new histopathologically proven cancers reporting to its various clinical departments. Data regarding age, gender and site were collected. A standardized hospital-based cancer registries core form was used for the collection of the data.</p><p><strong>Result: </strong>From the year 2017-2021 a total of 12,827 cancer patients were registered in our HBCR. From the total number 7,583 (59.12%) were males and 5,244 (40.88%) were females. In these 5 years 2,874 (22.4%) were registered in our hospital in the age group of 15-39 years (AYA) and 9953 (77.59%) were 40 and above the 40 years of age. In case of females breast cancer in adolescents (15-29) accounts about 6.77% next to breast cancer ovarian cancer accounts about 3.38%, while as in case of adults (29-39) the breast cancer remains at the highest percentage of 12.12% but uterine cancer comes at the second number with 6.63% this picture continues in the older adults with breast cancer (9.7%) at the highest percentage and next to breast cancer uterine cancer remains at the second number. Head and neck cancer cases were highest in males in both the age groups of AYA population that is adolescents (15-29) and in adults (29-39) with 17.41% and 35.7% respectively. The time trends of AYA cancers and old age cancers from 2017 to 2021 in males was showing an increasing trend with 18.45% to 21.53% except for the year 2019 when the drop was found and it might be because of the Covid-19 pandemic in India. The time trend of AYA cancers and old age cancers from 2017 to 2021 in female patients was showing an increasing trend from 19.34% to 27.05%.</p><p><strong>Conclusion: </strong>This study was done to find out the cancer burden of AYAs. The purpose of this study was to find out the specific AYA cancer profile and highlight the need of targeted cancer control measures to reduce the cancer burden in this age group.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 5","pages":"1046-1051"},"PeriodicalIF":1.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145180723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intrapulmonary schwannoma - A rare case report.","authors":"Komal D Sawaimul, Charusheela Gore, Sonam M Dabaria, Snigdha Saikia","doi":"10.4103/jcrt.jcrt_152_25","DOIUrl":"10.4103/jcrt.jcrt_152_25","url":null,"abstract":"<p><strong>Abstract: </strong>Schwannomas are benign, slow-growing tumors of neural origin arising from the Schwann cells. They usually arise along the course of the nerves in the body. Lung is one of the rarest site for schwannoma, hence making its diagnosis more difficult. Biopsy and IHC play the pivotal role in reaching the final diagnosis. Thereby highlighting the significance of making a conclusive diagnosis of benign nerve tumors in these relatively rare places. We are presenting a 66-year-old male diagnosed as intrapulmonary schwannoma on histopathology and immunohistochemistry.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 5","pages":"1082-1084"},"PeriodicalIF":1.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145180688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intra-arterial chemotherapy for unilateral advanced intraocular retinoblastoma: A long-term review of a case series.","authors":"Yixiao Li, Minglei Han, Dan Song, Jing Li, Zhuang Liu, Xin Zhang, Liang Wang, Lei Guo","doi":"10.4103/jcrt.jcrt_2375_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2375_24","url":null,"abstract":"<p><strong>Background: </strong>The role of intra-arterial chemotherapy (IAC) for globe salvage treatment of retinoblastoma (RB) has been validated clinically; however, data on its long-term effects remain limited. This study examined the long-term stable salvage rate of IAC in treating RB and assessed its potential adverse effects.</p><p><strong>Methods: </strong>Patients diagnosed with unilateral advanced intraocular RB who achieved short-term globe salvage and began IAC treatment at our hospital between December 2016 and September 2019 were selected for this study. The collected clinical data included patient demographics, tumor stage, prior treatment history, course of IAC therapy, complications, combination therapy modalities outside of IAC, and long-term follow-up outcomes.</p><p><strong>Results: </strong>Thirty-nine patients were included with a mean age at initial IAC treatment of 1.84 ± 1.18 years. Tumors were located in the right and left eyes of 22 and 17 patients, respectively. Based on the International Intraocular Retinoblastoma Classification (IIRC) grouping, Group D comprised 61.54%, whereas Group E accounted for 38.46% of the cases. The patients received 122 IAC sessions, with a median of three per patient. Follow-up data revealed a 5-year stable globe salvage rate of 87.18% with no treatment-related complications in 15 cases. The primary long-term adverse effects included cataracts, ocular growth arrest, and choroidal retinal atrophy/optic nerve atrophy.</p><p><strong>Conclusions: </strong>IAC demonstrated excellent long-term therapeutic efficacy and safety for children with unilateral advanced intraocular RB.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"442-446"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Supine/prone position fixation treatment in cervical cancer radiotherapy.","authors":"Zhiman Zheng, Dongyue Liu, Yangmei Su","doi":"10.4103/jcrt.jcrt_2050_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2050_24","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to determine the correlation between bladder volume changes and set-up accuracy in cervical cancer patients undergoing radiotherapy.</p><p><strong>Methods: </strong>Forty patients who underwent intensity-modulated radiotherapy were divided into two groups based on their position during treatment: group A (supine) and group B (prone). Correlations between bladder volume changes and set-up accuracy were retrospectively analyzed using archived data and image files.</p><p><strong>Results: </strong>The rate of bladder volume change in group A (-3.99% [-24.51-31.53]) was significantly higher (Z = -2.724; P = 0.006) than that in group B (-14.95% [-41.63-7.64]). The set-up errors in the X (left-right), Y (cranial-caudal), and Z (anterior-posterior) directions were 0.05 ± 2.25 mm, 0.84 ± 2.63 mm, and 0.41 ± 2.35 mm, respectively, in group A and -0.31 ± 2.22 mm, -0.38 ± 2.88 mm, and 0.78 ± 3.41 mm, respectively, in group B. No significant differences in the X and Z directions were detected between the two groups; however, a significant difference was detected in the Y direction. The set-up error in the X direction was positively correlated with the rate of bladder volume change (r = 0.284; P = 0.010) in group A; no correlations were observed in the X, Y, and Z directions in group B.</p><p><strong>Conclusion: </strong>Patients in the prone position demonstrated better performance in the Y direction than those in the supine position. The set-up error in the X direction was positively correlated with the rate of bladder volume change among patients in the supine position.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"401-408"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144048538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proteomics analysis explored the changes in the tumor microenvironment of CT26 tumor-bearing mice after microwave ablation.","authors":"Huiwen Xue, Zhen Li, Lu Yu, Qianqian Lu, Siyi Niu, Jing Liang, Zhigang Wei, Xin Ye, Qi Xie","doi":"10.4103/jcrt.jcrt_2113_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2113_24","url":null,"abstract":"<p><strong>Background: </strong>Microwave ablation (MWA) effectively generates large high-temperature ablation zones. This modality achieves direct tumor destruction while stimulating antitumor immunity and potentially inducing abscopal effects, though with limited systemic efficacy. Emerging evidence suggests post-MWA tumor microenvironment (TME) modifications critically influence immune activation, yet the underlying mechanisms remain poorly understood. Notably, localized proteomic changes in the TME following MWA require comprehensive characterization to elucidate its immunomodulatory properties.</p><p><strong>Aim of the study: </strong>This study investigates proteomic changes in TME after MWA to identify critical protein signatures modulating antitumor immunity.</p><p><strong>Material and methods: </strong>This study utilized a Balb/c murine model with subcutaneous CT26 cell injections to assess MWA effects on the TME. MWA treatment (5 w-3 min) was administered using a microwave generator, followed by LC-MS analysis using a tims TOF Pro with gradient elution and parallel accumulation serial fragmentation data collection. Protein expression differences were analyzed via t-test and further interpreted with Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway bioinformatics.</p><p><strong>Results: </strong>MWA induced substantial proteomic changes, with 545 upregulated and 678 downregulated proteins compared to controls. Integrated bioinformatics analysis demonstrated significant alterations in biological processes, cellular components, and molecular functions, particularly enriched in tumor cell growth-related pathways. Protein interaction network analysis identified pivotal hub proteins such as cap-binding protein subunit 1 (NCBP1) and cell division cycle 5-like protein (CDC5L) potentially mediating cellular responses to MWA treatment.</p><p><strong>Conclusion: </strong>MWA significantly induced protein alterations in TME, with NCBP1 and CDC5L standing out as promising candidate targets for tumor treatment.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"494-503"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144045289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination of epirubicin and cyclophosphamide for the treatment of advanced pulmonary sarcomatoid carcinoma: A case report and literature review.","authors":"Ruoyu Deng, Jialing Lv, Fang Wang, Yanqiong Chen, Junfeng Wang, Lin Wang, Lixia Mu, Zhijun Zhang, Wen Zhang, Chao Zhang","doi":"10.4103/jcrt.jcrt_361_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_361_24","url":null,"abstract":"<p><strong>Abstract: </strong>Pulmonary sarcomatoid carcinoma (PSC) is a rare and atypical subset of non-small-cell lung cancer (NSCLC) characterized by its aggressive nature, poor prognosis, and limited responsiveness to conventional therapeutic modalities. The effectiveness of chemotherapy in managing PSC remains controversial, with platinum-based regimens often yielding unsatisfactory outcomes in advanced PSC patients. Herein, we present a male patient with PSC who did not have a driver gene mutation or express the programmed death ligand 1. He received combination chemotherapy of epirubicin and cyclophosphamide for the first time, which resulted in progression-free survival for seven months and a noteworthy partial tumor response. These findings suggest that the combination of epirubicin and cyclophosphamide might prove promising as a therapeutic option for patients diagnosed with PSC. Nevertheless, the significance of this novel approach necessitates further validation through high-quality clinical trials.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"512-517"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144047427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MSNs-loaded HMME and Erastin-mediated ferroptosis combined with sonodynamic therapy for HCC treatment.","authors":"Chang Zhao, Guchun Qin, Caixia Ling, Yang Zhao, Yunxi Huang, Zelong Jiang, Niqiang Zhou, Junjie Liu, Danke Su, Jinghang Jiang","doi":"10.4103/jcrt.jcrt_1531_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_1531_24","url":null,"abstract":"<p><strong>Background: </strong>Ferroptosis can have a major impact on the development and advancement of hepatocellular carcinoma (HCC) due to its clear association with heightened vulnerability to the disease. This study aimed to develop a novel nanoplatform to evaluate its effectiveness in in vivo and in vitro models of HCC.</p><p><strong>Methods: </strong>Erastin, a compound that induces iron-dependent cell death, and HMME, a sonosensitizer, were enclosed within mesoporous silica nanoparticles (MSNs). The nanoparticles were engineered to exhibit a responsive assembly-disassembly mechanism. Hydrophilic hyaluronic acid (HA) was utilized for conjugation modification to synthesize Erastin/HMME@MSNs-HA. In vivo and in vitro experiments were conducted to elucidate the antitumor mechanisms of this nanomaterial.</p><p><strong>Results: </strong>In the in vitro cellular experiments, Erastin/HMME@MSNs-HA was rapidly degraded by hyaluronidase, leading to increased endocytosis of the cancer cells. Cellular breakdown led to the generation of harmful reactive oxygen species (ROS), decreased glutathione levels, and increased lipid peroxidation, resulting in a decrease in mitochondrial membrane potential, dysfunctional mitochondria, reduced cell growth, and increased cell death. Additionally, the Erastin/HMME@MSNs-HA nanotherapy platform, when combined with ultrasound (US) treatment, exhibited significant therapeutic effectiveness against tumors in vivo. It induced significant cell death in cancerous tissues, decreased tumor growth, worsened tissue oxygen deprivation, and exhibited good compatibility with the body.</p><p><strong>Conclusion: </strong>These findings indicate that the nanoplatform can effectively alleviate tumor hypoxia while inducing apoptosis and ferroptosis, laying the foundation for enhancing the efficacy of ROS-mediated HCC therapy.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"465-476"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144047331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}